Beta-amyloid peptide interacts specifically with the carboxy-terminal domain of human apolipoprotein E: relevance to Alzheimer's disease

J Neurochem. 1999 Jan;72(1):230-7. doi: 10.1046/j.1471-4159.1999.0720230.x.

Abstract

Growing evidence indicates the involvement of apolipoprotein E (apoE) in the development of late-onset and sporadic forms of Alzheimer's disease, although its exact role remains unclear. We previously demonstrated that beta-amyloid peptide (Abeta) displays membrane-destabilizing properties and that only apoE2 and E3 isoforms inhibit these properties. In this study, we clearly demonstrate that the carboxy-terminal lipid-binding domain of apoE (e.g., residues 200-299) is responsible for the Abeta-binding activity of apoE and that this interaction involves pairs of apoE amphipathic alpha-helices. We further demonstrate that Abeta is able to inhibit the association of the C-terminal domain of apoE with lipids due to the formation of Abeta/apoE complexes resistant to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. On the contrary, the amino-terminal receptor-binding domain of apoE (e.g., residues 129-169) is not able to form stable complexes with Abeta. These data extend our understanding of human apoE-dependent binding of Abeta by involving the C-terminal domain of apoE in the efficient formation of apoE/Abeta complex.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / metabolism*
  • Amyloid beta-Peptides / metabolism*
  • Apolipoprotein E2
  • Apolipoprotein E3
  • Apolipoproteins E / chemistry
  • Apolipoproteins E / metabolism*
  • Binding Sites / physiology
  • Humans
  • Lipid Metabolism
  • Liposomes / metabolism
  • Membrane Fusion / physiology
  • Peptide Fragments / metabolism
  • Protein Structure, Secondary
  • Protein Structure, Tertiary

Substances

  • Amyloid beta-Peptides
  • Apolipoprotein E2
  • Apolipoprotein E3
  • Apolipoproteins E
  • Liposomes
  • Peptide Fragments